Overview

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of Ramelteon, once daily (QD), sublingual (SL), in adult participants with acute depressive episodes associated with Bipolar I disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda